Journal
CANCERS
Volume 11, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/cancers11030272
Keywords
glioblastoma; radiotherapy; CXCL12
Categories
Funding
- German Research Council [RTG2099]
- DKFZ-MOST Cooperation in Cancer Research [CA181]
Ask authors/readers for more resources
Radiotherapy is a mainstay in glioblastoma therapy as it not only directly targets tumor cells but also depletes the tumor microvasculature. The resulting intra-tumoral hypoxia initiates a chain of events that ultimately leads to re-vascularization, immunosuppression and, ultimately, tumor-regrowth. The key component of this cascade is overexpression of the CXC-motive chemokine ligand 12 (CXCL12), formerly known as stromal-cell derived factor 1 (SDF-1). We here review the role of CXCL12 in recruitment of pro-vasculogenic and immunosuppressive cells and give an overview on future and current drugs that target this axis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available